The black market for new psychoactive substances has been constantly evolving and the substances that appear on this market cause a considerable number of issues, in extreme cases leading to human deaths. While monitoring the drug black market, we detected a sample of a dissociative anesthetic methoxphenidine, the salt of which contained an unusual anion in the form of bromo- and chloro-zincate complex. Concerning the unknown and potentially hazardous properties of this sample, we performed an in vitro cytotoxicity screening in cell lines of various origins (e.g., kidney, liver, bladder) which was compared with the toxicity results of the methoxphenidine standard prepared for this purpose. The street methoxphenidine sample exhibited markedly higher toxicity than the standard, which was probably caused by the anion impurity. Since it is not usual to analyze anions in salts of novel psychoactive substances, but such samples may be commonly available at the drug black market, we have developed a method for their identification with X-ray powder diffraction (XRPD), which also enabled us to distinguish between different polymorphs/solvates of methoxphenidine that were crystallized in the laboratory. XRPD offers additional data about samples, which may not be discovered by routine techniques, and in some cases, they may help to find out essential information.

Department of Biochemistry and Microbiology University of Chemistry and Technology Prague Technická 5 166 28 Prague Czech Republic

Department of Experimental Neurobiology National Institute of Mental Health Topolová 748 250 67 Klecany Czech Republic

Department of Inorganic Chemistry University of Chemistry and Technology Prague Technická 5 166 28 Prague Czech Republic

Department of Solid State Chemistry University of Chemistry and Technology Prague Technická 5 166 28 Prague Czech Republic

Forensic Laboratory of Biologically Active Substances Department of Chemistry of Natural Compounds University of Chemistry and Technology Prague Technická 5 166 28 Prague Czech Republic

Zobrazit více v PubMed

European Monitoring Centre for Drugs and Drug Addiction . European Drug Report 2021: Trends and Developments. European Monitoring Centre for Drugs and Drug Addiction; Luxembourg: 2021.

Jurásek B., Kuchař M. Methoxfenidin. Drugs Forensics Bull. 2017;23:3–7.

Zanos P., Moaddel R., Morris P.J., Georgiou P., Fischell J., Elmer G.I., Alkondon M., Yuan P., Pribut H.J., Singh N.S., et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–486. doi: 10.1038/nature17998. PubMed DOI PMC

Yang Y., Cui Y., Sang K., Dong Y., Ni Z., Ma S., Hu H. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554:317–322. doi: 10.1038/nature25509. PubMed DOI

Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–964. doi: 10.1126/science.1190287. PubMed DOI PMC

Dolgin E. Rapid antidepressant effects of ketamine ignite drug discovery. Nat. Med. 2013;19:8. doi: 10.1038/nm0113-8. PubMed DOI

Zanos P., Gould T.D. Mechanisms of ketamine action as an antidepressant. Mol. Psychiatry. 2018;23:801–811. doi: 10.1038/mp.2017.255. PubMed DOI PMC

Zhang K., Fujita Y., Hashimoto K. Lack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model. Sci. Rep. 2018;8:4007. doi: 10.1038/s41598-018-22449-9. PubMed DOI PMC

Wood D.M., Davies S., Puchnarewicz M., Johnston A., Dargan P.I. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur. J. Clin. Pharmacol. 2012;68:853–856. doi: 10.1007/s00228-011-1199-9. PubMed DOI

Dargan P.I., Tang H.C., Liang W., Wood D.M., Yew D.T. Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin. Toxicol. 2014;52:176–180. doi: 10.3109/15563650.2014.892605. PubMed DOI

Wallach J., Kang H., Colestock T., Morris H., Bortolotto Z.A., Collingridge G.L., Lodge D., Halberstadt A.L., Brandt S.D., Adejare A. Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS ONE. 2016;11:e0157021. doi: 10.1371/journal.pone.0157021. PubMed DOI PMC

Berger M.L., Schweifer A., Rebernik P., Hammerschmidt F. NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. Bioorg. Med. Chem. 2009;17:3456–3462. doi: 10.1016/j.bmc.2009.03.025. PubMed DOI

Luethi D., Hoener M.C., Liechti M.E. Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems. Eur. J. Pharmacol. 2018;819:242–247. doi: 10.1016/j.ejphar.2017.12.012. PubMed DOI

Gray N.M., Cheng B.K. Preparation of 1,2-Diarylethylamines for Treatment of Neurotoxic Injury. Patent EP346791A1. 1989 December 20;

McLaughlin G., Morris N., Kavanagh P.V., Power J.D., O’Brien J., Talbot B., Elliott S.P., Wallach J., Hoang K., Morris H., et al. Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta-and para-substituted isomers. Drug Test. Anal. 2016;8:98–109. doi: 10.1002/dta.1800. PubMed DOI

European Monitoring Centre for Drugs and Drug Addiction . Early Warning System: Unpublished Reports. European Monitoring Centre for Drugs and Drug Addiction; Luxembourg: 2017.

Helander A., Beck O., Bäckberg M. Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin. Toxicol. 2015;53:446–453. doi: 10.3109/15563650.2015.1033630. PubMed DOI

Hofer K.E., Degrandi C., Müller D.M., Zürrer-Härdi U., Wahl S., Rauber-Lüthy C., Ceschi A. Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine. Clin. Toxicol. 2014;52:1288–1291. doi: 10.3109/15563650.2014.974264. PubMed DOI

Stachel N., Jacobsen-Bauer A., Skopp G.A. Methoxydiphenidine-impaired driver. Int. J. Leg. Med. 2016;130:405–409. doi: 10.1007/s00414-015-1280-5. PubMed DOI

Elliott S.P., Brandt S.D., Wallach J., Morris H., Kavanagh P.V. First reported fatalities associated with the “research chemical” 2-methoxydiphenidine. J. Anal. Toxicol. 2015;39:287–293. doi: 10.1093/jat/bkv006. PubMed DOI

Erowid Contributors Methoxphenidine Reports. [(accessed on 10 January 2021)]. Available online: https://www.erowid.org/experiences/subs/exp_Methoxphenidine.shtml.

PsychonautWiki Contributors Methoxphenidine. [(accessed on 10 January 2021)]. Available online: https://psychonautwiki.org/wiki/Methoxphenidine.

Lam R.P.K., Yip W.L., Tsui M.S.H., Ng S.W., Ching C.K., Mak T.W.L. Severe rhabdomyolysis and acute kidney injury associated with methoxphenidine. Clin. Toxicol. 2016;54:464–465. doi: 10.3109/15563650.2016.1157724. PubMed DOI

Winstock A.R., Mitcheson L., Gillatt D.A., Cottrell A.M. The Prevalence and Natural History of Urinary Symptoms among Recreational Ketamine Users. BJU Int. 2012;110:1762–1766. doi: 10.1111/j.1464-410X.2012.11028.x. PubMed DOI

Kjellgren A., Jonsson K. Methoxetamine (MXE)—A Phenomenological Study of Experiences Induced by a “Legal High” from the Internet. J. Psychoact. Drugs. 2013;45:276–286. doi: 10.1080/02791072.2013.803647. PubMed DOI PMC

Hur K., Kim S., Ma S., Lee B., Ko Y., Seo J., Kim S., Kim Y., Sung S., Lee Y., et al. Methoxphenidine (MXP) Induced Abnormalities: Addictive and Schizophrenia-related Behaviours Based on an Imbalance of Neurochemicals in the Brain. Br. J. Pharmacol. 2021;178:3869–3887. doi: 10.1111/bph.15528. PubMed DOI

Champeau W., Eiden C., Gambier J., Peyriere H. Methoxphenidine Use Disorder. J. Clin. Psychopharmacol. 2017;37:376–377. doi: 10.1097/JCP.0000000000000684. PubMed DOI

Stodůlková E., Man P., Kolařík M., Flieger M. High-performance liquid chromatography–off line mass spectrometry analysis of anthraquinones produced by Geosmithia lavendula. J. Chromatogr. A. 2010;1217:6296–6302. doi: 10.1016/j.chroma.2010.08.009. PubMed DOI

Stodůlková E., Císařová I., Kolařík M., Chudíčková M., Novák P., Man P., Kuzma M., Pavlů B., Černý J., Flieger M. Biologically Active Metabolites Produced by the Basidiomycete Quambalaria cyanescens. PLoS ONE. 2015;10:e0118913. doi: 10.1371/journal.pone.0118913. PubMed DOI PMC

Jurásek B., Bartůněk V., Huber Š., Kuchař M. X-ray powder diffraction—A non-destructive and versatile approach for the identification of new psychoactive substances. Talanta. 2019;195:414–418. doi: 10.1016/j.talanta.2018.11.063. PubMed DOI

Haddad A., Comanescu M.A., Green O., Kubic T.A., Lombardi J.R. Detection and quantitation of trace fentanyl in heroin by surface-enhanced Raman spectroscopy. Anal. Chem. 2018;90:12678–12685. doi: 10.1021/acs.analchem.8b02909. PubMed DOI

Isaacs R.C.A. A structure–reactivity relationship driven approach to the identification of a color test protocol for the presumptive indication of synthetic cannabimimetic drugs of abuse. Forensic Sci. Int. 2014;242:135–141. doi: 10.1016/j.forsciint.2014.06.027. PubMed DOI

Schneider S., Meys F. Analysis of illicit cocaine and heroin samples seized in Luxembourg from 2005–2010. Forensic Sci. Int. 2011;212:242–246. doi: 10.1016/j.forsciint.2011.06.027. PubMed DOI

Morelato M., Franscella D., Esseiva P., Broséus J. When does the cutting of cocaine and heroin occur? The first large-scale study based on the chemical analysis of cocaine and heroin seizures in Switzerland. Int. J. Drug Policy. 2019;73:7–15. doi: 10.1016/j.drugpo.2019.07.025. PubMed DOI

Peck Y., Clough A.R., Culshaw P.N., Liddell M.J. Multi-drug cocktails: Impurities in commonly used illicit drugs seized by police in Queensland, Australia. Drug Alcohol Depend. 2019;201:49–57. doi: 10.1016/j.drugalcdep.2019.03.019. PubMed DOI

American Addiction Centres What Is Meth Cut with? [(accessed on 20 October 2021)]. Available online: https://americanaddictioncenters.org/meth-treatment/cut-with.

Wang X., Baumann M.H., Xu H., Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse. 2004;53:240–248. doi: 10.1002/syn.20058. PubMed DOI

National Crime Agency . Recent Deaths Possibly Linked to Fentanyl. National Crime Agency; London, UK: 2017.

Morris H., Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Test. Anal. 2014;6:614–632. doi: 10.1002/dta.1620. PubMed DOI

Verweij A.M. Impurities in illicit drug preparations: Amphetamine and methamphetamine. Forensic Sci. Rev. 1989;1:1–11. PubMed

United Nations Office on Drugs and Crime . Cocaine: A Spectrum of Products, Cocaine Insights2. United Nations Office on Drugs and Crime; Vienna, Austria: 2021.

American Addiction Centres What Is Cocaine Cut with. [(accessed on 9 January 2021)]. Available online: https://americanaddictioncenters.org/cocaine-treatment/cut-with.

Triclinic Labs Inorganic Materials Analysis and Phase Identification Services. [(accessed on 9 January 2021)]. Available online: https://tricliniclabs.com/page-directory/materials-analysis-services/inorganic-materials-analysis-phase-identification-by-triclinic-labs.html.

Jurásek B., Bartůněk V., Huber Š., Fagan P., Setnička V., Králík F., Dehaen W., Svozil D., Kuchař M. Can X-Ray powder diffraction be a suitable forensic method for illicit drug identification? Front. Chem. 2020;8:499. doi: 10.3389/fchem.2020.00499. PubMed DOI PMC

Kotrlý M. Application of X-ray diffraction in forensic science; Proceedings of the Ninth European Powder Diffraction Conference; Prague, Czech Republic. 2–5 September 2004; München, Germany: Oldenbourg Wissenschaftsverlag; 2006. pp. 35–40.

Thatcher P.J., Briner G.P. The application of X-Ray powder diffraction to forensic science. Powder Diffr. 1986;1:320–324. doi: 10.1017/S0885715600011994. DOI

Folen V.A. X-Ray powder diffraction data for some drugs, excipients, and adulterants in illicit samples. J. Forensic Sci. 1975;20:348–372. doi: 10.1520/JFS10282J. PubMed DOI

Newman A. X-Ray powder diffraction in solid form screening and selection. Am. Pharm. Rev. 2011;14:44.

Bulska E., Bachliński R., Cyrański M.K., Michalska-Kacymirow M., Kośnik W., Małecki P., Grela K., Dobrowolski M.A. Comprehensive protocol for the identification and characterization of new psychoactive substances in the service of law enforcement agencies. Front. Chem. 2020;8:693. doi: 10.3389/fchem.2020.00693. PubMed DOI PMC

Disregard Everything I Say MXP, Broken Down and Described. [(accessed on 10 January 2021)]. Available online: https://disregardeverythingisay.com/post/79851082420/mxp-broken-down-and-described#.

Reddit MXP, Broken Down and Described (New Novel Dissociative) [(accessed on 9 January 2021)]. Available online: https://www.reddit.com/r/Psychonaut/comments/20m5j8/mxp_broken_down_and_described_new_novel/